Who
Rajkumar Patil V
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, OKYO Pharma.
In numbers
- Trades disclosed
- 4
- Buys
- 1
- Sells
- 0
- Bought
- $10K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 27 Jul 2026
- Last trade
- 27 Jul 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Jul – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Jul 2026filed 7 Aug 2026 | OKYO OKYO PharmaBiotechnology | SEC FORM 4 Bought | $5,0113,363 at $1.49 | filing |
| 27 Jul 2026filed 7 Aug 2026 | OKYO OKYO PharmaBiotechnology | SEC FORM 4 Bought | $5,0113,363 at $1.49 | filing |
| 27 Jul 2026filed 29 Jul 2026 | OKYO OKYO PharmaBiotechnology | SEC FORM 4 Code A | $5,0113,363 at $1.49 | filing |
| 27 Jul 2026filed 29 Jul 2026 | OKYO OKYO PharmaBiotechnology | SEC FORM 4 Code A | $5,0113,363 at $1.49 | filing |
News
OKYO Pharma Begins Phase 3 Trial Of Urcosimod For Neuropathic Corneal PainOKYO · rttnews.com · 6 Oct 2026OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain | Company AnnouncementOKYO · investegate.co.uk · 6 Oct 2026
0 headlines in the last 90 days name Rajkumar Patil V; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.